Last reviewed · How we verify
AZD9550
AZD9550 is a small molecule that acts as a selective and potent inhibitor of the PI3K delta (p110δ) subunit.
AZD9550 is a small molecule that acts as a selective and potent inhibitor of the PI3K delta (p110δ) subunit. Used for Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), Relapsed or refractory follicular lymphoma.
At a glance
| Generic name | AZD9550 |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta (p110δ) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting PI3K delta, AZD9550 disrupts the signaling pathways involved in B-cell activation and proliferation, leading to its therapeutic effects. This mechanism is particularly relevant in the treatment of certain types of blood cancers.
Approved indications
- Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
- Relapsed or refractory follicular lymphoma
Common side effects
- Neutropenia
- Thrombocytopenia
- Anemia
Key clinical trials
- A Study to Investigate the Effect of AZD6234, AZD9550, and a Combination of AZD9550 and AZD6234 on Pharmacokinetics of Combined Oral Contraceptive Ethinyl Estradiol/Levonorgestrel in Healthy Female Participants Living With Overweight or Obesity (PHASE1)
- A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone (PHASE2)
- This is a Multi-centre, Multi-drug, Platform Study in Chinese Participants Living With Obesity / Overweight (PHASE2)
- A Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight (PHASE1, PHASE2)
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AZD9550 CI brief — competitive landscape report
- AZD9550 updates RSS · CI watch RSS
- AstraZeneca portfolio CI